Robert Discordia Is The Chief Operating Officer of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) And They Just Spent US$88k On Shares

Simply Wall St
August 14, 2019

Even if it's not a huge purchase, we think it was good to see that Robert Discordia, the Chief Operating Officer of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) recently shelled out US$88k to buy stock, at US$5.86 per share. While that isn't the hugest buy, it actually boosted their shareholding by 99%, which is good to see.

See our latest analysis for Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings Insider Transactions Over The Last Year

In fact, the recent purchase by Robert Discordia was the biggest purchase of Corbus Pharmaceuticals Holdings shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at around the current price of US$6.10. Of course they may have changed their mind. But this suggests they are optimistic. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. Happily, the Corbus Pharmaceuticals Holdings insiders decided to buy shares at close to current prices.

In the last twelve months insiders paid US$244k for 38466 shares purchased. Corbus Pharmaceuticals Holdings insiders may have bought shares in the last year, but they didn't sell any. The chart below shows insider transactions (by individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

NasdaqGM:CRBP Recent Insider Trading, August 14th 2019
NasdaqGM:CRBP Recent Insider Trading, August 14th 2019

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Insiders own 5.5% of Corbus Pharmaceuticals Holdings shares, worth about US$22m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Does This Data Suggest About Corbus Pharmaceuticals Holdings Insiders?

It is good to see recent purchasing. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. Insiders likely see value in Corbus Pharmaceuticals Holdings shares, given these transactions (along with notable insider ownership of the company). If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Simply Wall St character - Warren

Simply Wall St

Simply Wall St is a financial technology startup focused on providing unbiased, high-quality research coverage on every listed company in the world. Our research team consists of equity analysts with a public, market-beating track record. Learn more about the team behind Simply Wall St.